
March 6 (Reuters) - A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's LLY.N popular weight-loss drug Zepbound in the U.S.
The decision was filed late on Wednesday in response to a lawsuit brought by a compounding industry group that challenged the U.S. Food and Drug Administration's decision to bar those copies.